# US 2019/0167626 A1 · Retinal derivatives and methods for the use thereof for the treatment of visual disorders

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2019/0167626 A1
- Document ID: US20190167626A1
- Status: Published application
- Kind: A1
- Application number: 16/177,076
- Filed: 2018-10-31
- Published: 2019-06-06
- Earliest claimed: 2004-06-18
- Assignees: University of Washington
- Applicants: University of Washington
- Inventors: Krzysztof Palczewski; Matthew Batten
- Web page: https://patentgrep.com/patent/US20190167626A1

## CPC

- A61K 31/225: Polycarboxylic acids
- A61K 9/0019: {Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00)}
- A61K 9/0048: {Eye, e.g. artificial tears}
- A61K 9/0053: {Mouth and digestive tract, i.e. intraoral and peroral administration}
- A61K 31/215: of carboxylic acids
- A61K 31/22: of acyclic acids, e.g. pravastatin
- A61P 3/02: Nutrients, e.g. vitamins, minerals
- A61P 27/00: Drugs for disorders of the senses
- A61P 27/02: Ophthalmic agents
- C07C 403/10: by etherified hydroxy groups
- C07C 403/12: by esterified hydroxy groups
- C07C 403/14: having side-chains substituted by doubly-bound oxygen atoms
- C07C 403/20: having side-chains substituted by carboxyl groups {or halides, anhydrides, or (thio)esters thereof}
- C07B 2200/09: Geometrical isomers
- C07C 2601/10: the ring being unsaturated
- C07C 2601/16: the ring being unsaturated
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07C: ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07B: GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR (preparation of carboxylic acid esters by telomerisation C07C67/47; telomerisation C08F)

## Abstract

Compositions of and methods for using synthetic retinal derivatives as retinoid replacements and opsin agonists are provided.

## Claims

### Claim 1

A retinyl ester selected from the group consisting of a 9-cis-retinyl ester and an 11-cis-retinyl ester, wherein the ester substituent comprises a carboxylate radical of a C3 to C22 polycarboxylic acid, with the proviso that the ester substituent is not tartrate.

### Claim 2 (depends on 1)

The retinyl ester of claim 1, which is a 9-cis-retinyl ester of a C3 to C22 polycarboxylate.

### Claim 3 (depends on 1)

The retinyl ester of claim 1, which is a 9-cis-retinyl ester of a C3 to C10 polycarboxylate.

### Claim 4 (depends on 3)

The retinyl ester of claim 3, wherein the 9-cis-retinyl ester is 9-cis-retinyl succinate, 9-cis-retinyl citrate, 9-cis-retinyl ketoglutarate, 9-cis-retinyl fumarate, 9-cis-retinyl malate or 9-cis-retinyl oxaloacetate.

### Claim 5 (depends on 1)

The retinyl ester of claim 1, which is an 11-cis-retinyl ester of a C3 to C22 polycarboxylate.

### Claim 6 (depends on 1)

The retinyl ester of claim 1, which is an 11-cis-retinyl ester of a C3 to C10 carboxylate.

### Claim 7 (depends on 6)

The retinyl ester of claim 6, wherein the 11-cis-retinyl ester is 11-cis-retinyl succinate, 11-cis-retinyl citrate, 11-cis-retinyl ketoglutarate, 11-cis-retinyl fumarate, 11-cis-retinyl malate or 11-cis-retinyl oxaloacetate.

### Claim 8 (depends on 1)

A pharmaceutical composition comprising the retinyl ester of claim 1 and a pharmaceutically acceptable vehicle.

### Claim 9 (depends on 8)

A pharmaceutical composition of claim 8, compounded as an opthalmological composition in an opthalmologically acceptable vehicle for administration to the eye topically or by intra-ocular injection.

### Claim 10

A method of restoring photoreceptor function in a mammal, comprising administering to a mammalian subject having an endogenous retinoid deficiency an effective amount of a synthetic retinal derivative, wherein the synthetic retinal derivative is converted into a retinal capable of forming a functional opsin/retinal complex,
wherein the synthetic retinal derivative is a 9-cis-retinyl ester, an 11-cis-retinyl ester, or a combination thereof;
wherein the ester substituent comprises a carboxylate radical of a C1-C10 monocarboxylic acid or a C2 to C22 polycarboxylic acid.

### Claim 11 (depends on 10)

The method of claim 10, wherein the synthetic retinal derivative is 9-cis-retinyl acetate or 11-cis-retinyl acetate.

### Claim 12 (depends on 10)

The method of claim 10, wherein the ester substituent comprises a carboxylate radical of a polycarboxylic acid of C3 to C10.

### Claim 13 (depends on 12)

The method of claim 12, wherein the ester substituent is selected from the group consisting of succinate, citrate, ketoglutarate, fumarate, malate and oxaloacetate.

### Claim 14 (depends on 10)

The method of claim 10, wherein the mammalian subject is human.

### Claim 15

A method of ameliorating loss of photoreceptor function in a mammal, comprising: administering an effective amount of a synthetic retinal derivative to the vertebrate eye, wherein the synthetic retinal derivative is converted into a retinal capable of forming a functional opsin/retinal complex,
wherein the synthetic retinal derivative is a 9-cis-retinyl, an 11-cis-retinyl ester, or a combination thereof;
wherein the ester substituent comprises a carboxylate radical of a C1-C10 monocarboxylic acid or a C2 to C22 polycarboxylic acid.

### Claim 16 (depends on 15)

The method of claim 15, wherein the synthetic retinal derivative is 9-cis-retinyl acetate or 11-cis-retinyl acetate.

### Claim 17 (depends on 15)

The method of claim 15, wherein the ester substituent comprises a carboxylate radical of a polycarboxylic acid of C3 to C10.

### Claim 18 (depends on 17)

The method of claim 17, wherein the ester substituent is selected from the group consisting of succinate, citrate, ketoglutarate, fumarate, malate and oxaloacetate.
